MOUNTAIN VIEW, Calif.,
April 6, 2016 /PRNewswire/ --
Omnicell, Inc. (NASDAQ: OMCL) is pleased to report that UW Health,
the system associated with the University of
Wisconsin-Madison, is adding the i.v.STATION ONCO™, which
provides robotic sterile compounding of oncology admixtures, to
their pharmacy automation solutions. UW Health selected the Aesynt
product, now part of Omnicell's product portfolio, for use in the
drug distribution process at their main University Hospital as well
as in three additional facilities in their health system. In
addition, the hospital is updating their existing ROBOT-Rx® automated medication dispensing
robot and upgrading their AcuDose-Rx® automated
dispensing cabinets. These and other products from Aesynt have
recently been added to the Omnicell portfolio, expanding Omnicell's
ability to support all key pharmacy distribution models, described
as follows:
- Centralized: Most medications are distributed from a
central location, and pharmacy staff help prepare and distribute
medications by patient to nursing units.
- Decentralized: Most medications are stored in automated
dispensing cabinets near patient care areas where nurses dispense
them by patient.
- Hybrid: This approach combines aspects of both
centralized and decentralized dispensing models based on the
specific capabilities of the pharmacy.
Omnicell is offering Aesynt's leading sterile IV compounding
technology, which includes the i.v.STATION ONCO being implemented
at UW Health to handle oncology and other hazardous preparations.
IV automation offers a safe, accurate and cost-effective solution
for compounding and dispensing IV admixtures. Adding this
automation enables the health care system to streamline compounding
processes, helping to simplify workflows, minimize employee
exposure to potentially dangerous materials, and support improved
care for oncology patients by eliminating medication errors. This
IV automation also helps to significantly improve efficiency in
drug delivery and allows clinicians to spend more time on
patient-facing activities.
In addition to the new IV technology, the main University
Hospital has upgraded their medication automation cabinets
throughout the hospital.
"Our plans for IV automation were first envisioned during
reconstruction of our cancer center last year," said Steve Rough, director of pharmacy at UW
Hospitals and Clinics. "The goal is to keep both patients and
employees safe, and to minimize medication waste."
"The hybrid-pharmacy approach in our health system is designed
to support existing demand while ensuring the best use of our
clinical staff," said Brad Ludwig,
assistant director of pharmacy at UW Hospital and Clinics. "We are
working with members at all levels of our health system in
achieving a safe and efficient medication delivery model."
"We are pleased to work with long-time Aesynt partners at UW
Health to continue offering tailored medication distribution
solutions and processes to their facilities," said J. Christopher Drew, president, North American
Automation and Analytics for Omnicell. "By expanding our offering of
pharmacy products for centralized and decentralized distribution,
we are now able to provide our customers with increased
customization options along the full spectrum of medication and
supply automation products throughout the health care
continuum."
About UW Health
UW Health is the integrated health system of the University of Wisconsin-Madison serving more than
600,000 patients each year in the Upper Midwest and beyond with
1,400 physicians and 16,500 staff at six hospitals and 80
outpatient sites. UW Health is governed by the UW Hospitals and
Clinics Authority and partners with UW School of Medicine and
Public Health to fulfill their patient care, research, education
and community service missions.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating
innovative solutions to improve patient care, anywhere it is
delivered. Omnicell is a leading supplier of comprehensive
automation and business analytics software for medication and
supply management across the entire health care continuum—from the
acute care hospital setting, to post-acute skilled nursing and
long-term care facilities, to the patient's home.
Approximately 4,000 customers worldwide use Omnicell automation
and analytics solutions to increase operational efficiency, reduce
medication errors, deliver actionable intelligence and improve
patient safety. The recent acquisition of Aesynt adds distinct
capabilities, particularly in central pharmacy and IV robotics,
creating the broadest medication management product portfolio in
the industry.
The Omnicell SureMed® solution provides innovative
medication adherence packaging to help reduce costly hospital
readmissions. In addition, these solutions enable approximately
7,000 institutional and retail pharmacies worldwide to maintain
high accuracy and quality standards in medication dispensing and
administration while optimizing productivity and controlling
costs.
For more information about Omnicell, Inc. please
visit www.omnicell.com.
OMCL-G
Editor's Notes:
- All Omnicell news releases (financial, acquisitions, products,
technology etc.) are issued exclusively by PR Newswire and are
immediately thereafter posted on the company's external website,
omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks
of Omnicell, Inc.
- All other brand or product names may be trademarks or
registered trademarks of their respective companies.
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/uw-health-adds-new-iv-automation-capabilities-and-solutions-to-enhance-hybrid-drug-distribution-process-300246961.html
SOURCE Omnicell, Inc.